This article was originally published in The Tan Sheet
Color and appearance of potassium iodide (KI) tablets in federal agency, state and local emergency stockpiles should be monitored to assess stability, FDA states in a 1guidance on KI shelf life extension slated for publication in the Federal Register March 8. Although numerous studies have proven the supplements do not degrade significantly over time, FDA suggests "samples of three batches of KI tablets from each manufacturer be selected and stored under controlled conditions of temperature and humidity and that the samples be tested periodically for compliance with [U.S. Pharmacopeia] assay and dissolution specifications." The guidance, which updates a similar release from April 2002, has been revised to recommend confirmatory testing after two years...
You may also be interested in...
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.